EYE-103 is under clinical development by Eyebiotech and currently in Phase III for Diabetic Macular Edema. According to GlobalData, Phase III drugs for Diabetic Macular Edema have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how EYE-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EYE-103 overview
EYE-103 is under development for the treatment of diabetic retinopathy, retinopathy of prematurity, diabetic macular edema and neovascular age-related macular degeneration. It is a tetravalent antibody-like molecule (ANT) developed based on a protein engineering platform and acts by targeting frizzled receptor 4 and low-density lipoprotein receptor related protein 5 (LRP5). It is administered through intravitreal route.
Eyebiotech overview
Eyebiotech is a ophthalmology biotechnology company developing and delivering therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. Eyebiotech is headquartered in London, Greater London, the UK.
For a complete picture of EYE-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
